** You must be at least 18 years old to purchase from "" or to view the website. These statements have not been evaluated by the Food and Drug Administration (FDA). The information and/or products on "" are not a replacement for medical advice. None of the products are drugs and none of the information on this website should be taken as medical advice. You may NOT use any information/products on this site as advice to diagnose, treat or cure any disease. provides strong alternatives to the toxic drugs listed on top of this page. Please consult a medical professional before changing your diet or training regiment or starting the use of supplements.
* These products are not intended to diagnose, treat, cure or prevent any disease. These statements have not been evaluated by the Food and Drug Administration (FDA). This website and the associated domain names "roid-" are representative of ingredients which may enhance blood levels of hormones in the body. This site is offering this extremely strong alternative to the highly toxic drug listed on the top of the page. These products are not drugs. Our products are not to be used by anyone under 18 years of age. The information provided on this site is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem.
After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol.  In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism .  After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .